Dr. med. Markus Eckstein


Pathologisches Institut

Publications (Download BibTeX)

Go to first page Go to previous page 1 of 3 Go to next page Go to last page

Sikic, D., Wirtz, R.M., Wach, S., Dyrskjot, L., Erben, P., Bolenz, C.,... Keck, B. (2019). Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent Cohorts. Translational Oncology, 12(4), 661-668. https://dx.doi.org/10.1016/j.tranon.2019.01.005
Martini, T., Heinkele, J., Mayr, R., Weis, C.-A., Wezel, F., Wahby, S.,... Erben, P. (2019). Erratum to 'Predictive value of lymphangiogenesis and proliferation markers on mRNA level in urothelial carcinoma of the bladder after radical cystectomy' [Urologic Oncology: Seminars and Original Investigations 36/12 (2018) 505-534]. Urologic Oncology-Seminars and Original Investigations, 37(3), 227-227. https://dx.doi.org/10.1016/j.urolonc.2018.12.019
Breyer, J., Wirtz, R.M., Erben, P., Rinaldetti, S., Worst, T.S., Stoehr, R.,... Otto, W. (2019). FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer. Bju International, 123(1), 187-196. https://dx.doi.org/10.1111/bju.14525
Eckstein, M., Erben, P., Kriegmair, M.C., Worst, T.S., Weiss, C.-A., Wirtz, R.M.,... Erlmeier, F. (2019). Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. European journal of cancer, 106, 234-243. https://dx.doi.org/10.1016/j.ejca.2018.11.007
Gevaert, T., Eckstein, M., Montironi, R., & Lopez-Beltran, A. (2019). Re: Maud Rijnders, Astrid A.M. van der Veldt, Tahlita C.M. Zuiverloon, et al. PD-L1 Antibody Comparison in Urothelial Carcinoma. Eur Urol 2019;75:538–40. European Urology, 75(6), e162-e163. https://dx.doi.org/10.1016/j.eururo.2019.01.038
Pfannstiel, C., Strissel, P., Chiappinelli, K.B., Sikic, D., Wach, S., Wirtz, R.M.,... Eckstein, M. (2019). The tumor immune microenvironment drives a prognostic relevance that correlates with bladder cancer subtypes. Cancer Immunology Research, 7(6), 923-938. https://dx.doi.org/10.1158/2326-6066.CIR-18-0758
Eckstein, M., Wirtz, R., Pfannstil, C., Wach, S., Stoehr, R., Breyer, J.,... Erben, P. (2018). A multicenter comparison of PD-L1 protein and mRNA expression in urothelial bladder cancer by immunohistochemistry and RT-qPCR (Checkpoint-Typer(C)): A round robin test by the BRIDGE-Consortium Germany. (pp. 81-81).
Eckstein, M., Wirtz, R.M., Pfannstil, C., Wach, S., Stoehr, R., Breyer, J.,... Erben, P. (2018). A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy. Oncotarget, 9(19), 15001-15014. https://dx.doi.org/10.18632/oncotarget.24531
Sikic, D., Wirtz, R., Wach, S., Dyrskjot, L., Erben, P., Bolenz, C.,... Keck, B. (2018). Analysis of androgen receptor mRNA expression in urothelial carcinoma of the bladder. (pp. 70-70).
Worst, T.S., Weis, C.-A., Stoehr, R., Bertz, S., Eckstein, M., Otto, W.,... Erben, P. (2018). CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making. Scientific Reports, 8(1). https://dx.doi.org/10.1038/s41598-018-32569-x

Last updated on 2017-05-09 at 02:00